Kyowa Hakko Kirin Co., Limited

La Jolla Institute for Allergy and Immunology

Jfe Chemical Corporation

Tomoyuki Tahara

Tetsuya Yoshino

Shiro Kataoka

Yoshikatsu Kanai

Kazumasa Hasegawa

Hitoshi Endou

Shinichiro Kato

Shane Crotty

Steve Granger

Sandra Rickert

Lilia Koriazova

Rachel Soloff Nugent

Paul Rogers

Aihua Song

The present invention provides a Li-ion secondary cell negative-electrode material with which it is possible to adequately suppress reductive decomposition of a liquid electrolyte by an active material during charging, the Li-ion secondary cell negative-electrode material exhibiting a high discharge capacity that exceeds the theoretical capacity of graphite and exceptional initial charging efficiency and cycle characteristics. In this negative-electrode material for a Li-ion secondary cell, the surfaces of particles of SiO(O&#x2264;x&#x3c;2) contain Li and at least one metallic element M selected from among Si, Al, Ti, and Zr, and have a coating of a Li-containing oxide comprising a composition in which M/Li&#x3e;5 with respect to the molar ratio.

Negative-electrode material for Li-ion secondary cell, method for manufacturing said material, negative electrode for Li-ion-secondary-cell, and Li-ion secondary cell

A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.

Anti-CD98 antibody processes

The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus H3L envelope protein, and combinations thereof.

Vaccinia virus H3L and B5R specific monoclonal antibodies and methods of making and using same

The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to pox virus H3L envelope protein, and combinations thereof.

Anti-CD98 antibody

The invention relates to IL-1O Receptor alpha (IL-1OR&#x3b1;) antibodies and subsequences thereof, human and humanized IL-10 Receptor alpha (IL-IOR&#x3b1;) antibodies and subsequences thereof, isolated and purified IL-10 Receptor alpha (IL-1OR&#x3b1;) antibodies and subsequences thereof, compositions including IL-10 Receptor alpha (IL-1OR&#x3b1;) antibodies and subsequences thereof, and methods that employ IL-10 Receptor alpha (IL-1OR&#x3b1;) antibodies and subsequences thereof. The invention includes among other things, methods of treating a pathogen infection, pathogen reactivation, and methods of vaccinating or immunizing against a pathogen infection, which include, for example, administering an IL-10 Receptor alpha (IL-1OR&#x3b1;) antibody or subsequence, to treat a pathogen infection, pathogen reactivation or for vaccination or immunization.

Interleukin 10 receptor, (IL-10R) antibodies

Growing community of inventors

San Diego, CA, United States of America

Tomoyuki Tahara